NCT03708341View on ClinicalTrials.gov

Exogenous Melatonin in Intensive Care Unit Chronodisruption

PHASE3RecruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions
Sleep DeprivationIntensive Care Psychosis
Interventions
DRUG

Melatonin 5 mg

Systematic daily administration of melatonin 5 mg during patient's ICU stay

DRUG

Placebo Oral Tablet

Systematic daily administration of placebo during patient's ICU stay

Trial Locations (1)

Unknown

RECRUITING

Hotel Dieu de France, Beirut

All Listed Sponsors
lead

Saint-Joseph University

OTHER

NCT03708341 - Exogenous Melatonin in Intensive Care Unit Chronodisruption | Biotech Hunter | Biotech Hunter